

Erratum to: Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Lesley J. Scott

Published online: 27 November 2014
© Springer International Publishing Switzerland 2014

Erratum to: Drugs (2014) 74:1769–1784
DOI 10.1007/s40265-014-0298-1

Page 1777, column 2, section 4.4, paragraph 2, lines 3–8: The following sentence, which previously read:

“At 52 weeks, adjusted mean changes from baseline in daily insulin dose were significantly lower in the empagliflozin 10 and 25 mg groups than in the placebo group (+1.3 and -1.1 vs. +10.2 IU/day; both $p < 0.01$); respective baseline mean daily doses were 90.4, 89.4 and 99.5 IU/day [38].”

should read:

“At 78 weeks, adjusted mean changes from baseline in daily insulin dose were significantly lower in the empagliflozin 10 and 25 mg groups than in the placebo group (-1.21 and -0.47 vs. +5.45 IU/day; both $p < 0.01$); respective baseline mean daily doses were 45.13, 48.43 and 47.84 IU/day [38].”

The online version of the original article can be found under doi:[10.1007/s40265-014-0298-1](https://doi.org/10.1007/s40265-014-0298-1).

L. J. Scott (✉)
Springer, Private Bag 65901, Mairangi Bay 0754, Auckland,
New Zealand
e-mail: demail@springer.com